"The Marijuana Conspiracy" and The Research Dodge

The Canadian film "The Marijuana Conspiracy," released in the US on 4/20, illustrates in part the absurdity and politicization of research into marijuana's effects. The film, based on a study that happened in 1972 in Toronto, begins with footage of politicians (all old, white men) railing against marijuana use. We then meet an old, white male addiction researcher downing a martini who hires an unscrupulous hippie-type researcher out for fame and fortune who recruits young women pot smokers for a study aimed at discovering marijuana's harms. 

The women were locked in a building for 98 days, with no escape to take a walk outside or see their friends or families, while being constantly observed by researchers. Even the joints they were given to smoke nightly couldn't counter the effects of this strange, unnatural setting and the film (and doubtlessly the study itself) devolves into melodrama. Like many rats put in a cage, the women were pointlessly overdosed with pot. Yet, they remained productive and experienced no ill effects, although some members of both the smoking group and the nonsmoking control groups had difficulty assimilating after their isolation. The results of the study were never publicized due to political reasons, and it took decades for Canada to finally legalize pot (the US still hasn't done so). 

Jocelyn Elders Co-Authors Oped Slamming AMA's Position on Marijuana

Elders depicted at the 2016 Oakland Museum "Altered State" exhibit

Former US Surgeon General Jocelyn Elders has co-authored an oped on CNN.com  blasting the AMA's policy on marijuana as racist and out of step with the times. It states:

The AMA actively supports cannabis prohibition, a cornerstone of the drug war, even as it hypocritically condemns systemic racism for creating inequity and limiting access to health care among communities of color. The organization fails to appreciate or chooses to ignore the fact that the uneven application of laws on cannabis prohibition contributes to poverty, which is one of the largest obstacles to health care access in communities of color. 

Cannabis is demonstrably safer for the vast majority of adults than alcohol, but the AMA doesn't call for a return to alcohol prohibition. Cannabis is far less harmful to adults than tobacco, but the AMA advocates tighter regulation rather than the prohibition of tobacco products. While the medical community offers an evidence-based, nuanced assessment of the health effects of cannabis, the AMA hyperbolically asserts that "without question, the public health risks (of legalization) are immense." 

Cannabis use is not the "immense" public health threat that the AMA claims, but its prohibition is a powerful weapon of racially biased policing. In 2019, US law enforcement made over 500,000 arrests for simple cannabis possession alone. An American Civil Liberties Union report from 2018 found that Black people in America are nearly four times more likely than Whites to be arrested for cannabis possession, despite similar usage rates between the two groups.

New Archeological Finds Point to Ancient Cannabis Use, Despite Prejudice of Some Scholars

“For as long as there has been civilization, there have been mind-altering drugs,” begins an article in the 4/20/18(!) edition of Science magazine.

Alcohol was fermented at least 10,000 years ago in the Fertile Crescent, the article continues, and psychoactive drugs “were an important part of culture. But the Near East had seemed curiously drug-free—until recently. Now, new techniques for analyzing residues in excavated jars and identifying tiny amounts of plant material suggest that ancient Near Easterners indulged in a range of psychoactive substances."

Australian archeologist David Collard, who has found signs of ritual opium use on Cyprus dating back more than 3000 years, was interviewed for the article, and said that some senior researchers consider the topic “unworthy of scholarly attention.” He told Science, “The archeology of the ancient Near East is traditionally conservative.”

By Einsamer Schütze [GFDL (http://www.gnu.org/copyleft/fdl.html) or CC BY-SA 3.0
(https://creativecommons.org/licenses/by-sa/3.0)], from Wikimedia Commons

The Yamnaya people, who traveled from Central Asia around 3000 BCE “and left their genes in most living Europeans and South Asians,” appear to have carried cannabis, which originates in East and Central Asia, to Europe and the Middle East.” They also brought with them the wheel and possibly Indo-European languages.

The Yamnaya were part of the "corded ware culture," so named because of the cord patterns in their pottery, and possibly pointing to the use of hemp for rope.

In 2016, a team from the German Archeological Institute and the Free University, both in Berlin, found residues and botanical remains of cannabis at Yamnaya sites across Eurasia. Digs in the Caucasus have uncovered braziers containing seeds and charred remains of cannabis dating to about 3000 BCE.

Feds Squash Doctor Training on Cannabis for Pain

As reported by the Associated Press, The American Academy of Pain Medicine has cancelled its plans for a webinar in July aimed at training doctors on the use of cannabis instead of opiates for pain. The cancellation followed "a request from the U.S. government agency that provided the funding." The agency was the Substance Abuse and Mental Health Services Administration, or SAMHSA, a division of the U.S. Department of Health and Human Services (HHS).

“We cannot speak to the reason that SAMHSA has asked that we not proceed with this webinar, but the webinar will no longer take place,” AAPM spokeswoman Megan Drumm said in an email to AP.

Scheduled speakers for the course, titled "Opioid Prescribing Amidst Changing Cannabis Laws,” were pain doctors from the University of Texas and the University of California, San Diego. They planned to cover how to select patients for medical cannabis, appropriate products and doses, and how to “wean opioids in patients on chronic opioid therapy,” according to the course description.

A study released in March concluded that only 9% of medical schools are teaching students about cannabis as a medicine.  “I’m not surprised by the findings,” commented Mark Steven Wallace, MD, chair of the Division of Pain Medicine at UC San Diego Health and one of the speakers scheduled for the now-cancelled webinar. Dr. Wallace said there is an opportunity for experiential learning on the topic at pain clinics like his, where medical cannabis is recommended “every day.”

Dr. Wallace has observed that some chronic pain patients arrive at the clinic after having tried and responded negatively to medical marijuana. “Quite often that’s because they have not been using the right formulation or have been using too high a dose,” he said. “We find that a low dose of a strain that combines THC [tetrahydrocannabinol] with CBD [cannabidiol] is most effective, but you won’t find that mentioned in the literature or taught in the classroom.” 

SSRIs increasingly prescribed during pregnancy, without much study on their effects

Lead researcher Claudia Lugo-Candelas

Researchers from Columbia University, the Keck School of Medicine, and the Institute for the Developing Mind in Los Angeles, have published a new study on how infants' brains are affected when their mothers take SSRIs for depression during pregnancy. SSRIs include Celexa, Lexapro, Prozac, Luvox, Paxil and Zoloft, and are used by 1 in 10 adults in the US.

Excerpts from the study:

Selective serotonin reuptake inhibitor (SSRI) use among pregnant women is increasing, yet the association between prenatal SSRI exposure and fetal neurodevelopment is poorly understood.

A cohort study conducted at Columbia University Medical Center and New York State Psychiatric Institute included 98 infants: 16 with in utero SSRI exposure, 21 with in utero untreated maternal depression exposure, and 61 healthy controls. Our findings suggest that prenatal SSRI exposure has an association with fetal brain development, particularly in brain regions critical to emotional processing....To our knowledge, this is the first study to report increased volumes of the amygdala and insular cortex, as well as increased WM connection strength between these 2 regions, in prenatally SSRI-exposed infants.